<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395329</url>
  </required_header>
  <id_info>
    <org_study_id>BYS-MD-57</org_study_id>
    <nct_id>NCT01395329</nct_id>
  </id_info>
  <brief_title>Nebivolol and the Endothelin (ET)-1 System</brief_title>
  <acronym>NETS</acronym>
  <official_title>Nebivolol and the Endothelin (ET)-1 System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor tone
      in adult humans with elevated blood pressure to a greater extent than either metoprolol or
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. The investigators hypothesize that nebivolol will reduce ET-1-mediated vasoconstrictor
           tone in adult humans with elevated blood pressure to a greater extent than either
           metoprolol or placebo.

        2. The investigators further hypothesize that reducing ET-1 vasoconstrictor activity
           contributes to the improvement in endothelial vasodilator function associated with
           nebivolol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ET-1-mediated vasoconstrictor tone</measure>
    <time_frame>Forearm blood flow will be measured at week 3 (before the 12 week drug or placebo intervention) and at week 15 (after the 12 week drug or placebo intervention).</time_frame>
    <description>Forearm blood flow is measured in response to Acetylcholine, Sodium Nitroprusside, BQ-123, BQ-788 and Acetylcholine combined with BQ-123 and BQ-788</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Prehypertension</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>5 mg tablet to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Nebivolol</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>100 mg tablet to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Toprol-XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>gelatin capsule to be taken by mouth once per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be men and women of all races and ethnic backgrounds aged 45-65 years.

          -  Subjects will be prehypertensive/hypertensive defined as resting systolic blood
             pressure &gt;130 mmHg and &lt; 160 mm Hg and/or diastolic blood pressure &gt;80 mmHg and &lt; 100
             mm Hg.

          -  All of the women in the study will be postmenopausal (at least 1 year from last
             menstrual cycle) and not receiving hormone replacement therapy (HRT) currently or in
             the preceding 3-year period.

          -  Lastly, candidates will be sedentary as determined from the Stanford Physical Activity
             Questionnaire (&lt;35 kcal/wk) and will not have engaged in any program of regular
             physical activity for at least 1 year prior to the study.

        Exclusion Criteria:

          -  Candidates who smoke (currently or in the past 7 years), report more than low-risk
             alcohol consumption as defined as no more than 14 standard drinks/wk and no more than
             4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for
             women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1Â½ ounces
             of 80-proof distilled spirits)

          -  Potential candidates who are taking cardiovascular-acting (i.e. statins, blood
             pressure medication an aspirin) medications will not be eligible.

          -  Fasting plasma glucose &gt;126 mg/dL.

          -  Potential candidates with a resting heart rate of &lt; 50 beats/minute will be excluded.

          -  Use of hormone replacement therapy.

          -  In hypertensive subjects, a seated systolic blood pressure greater than 160 mmHg or a
             seated diastolic blood pressure greater than 100 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher A DeSouza, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado at Boulder</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC-Boulder Clinical and Translational Research Center</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Colorado, Boulder</investigator_affiliation>
    <investigator_full_name>Christopher DeSouza</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 2, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

